Comparable Hotel EBITDA Growth
Comparable hotel EBITDA grew 6.2% (management stated), with December showing a particularly strong 12% increase in hotel EBITDA versus prior-year, reflecting traction from GrowAHT initiatives and revenue management.
RevPAR and Revenue Strength
Comparable hotel RevPAR increased 3% year-over-year in Q4; total revenue growth meaningfully exceeded RevPAR growth due to ancillary revenue initiatives.
Group Revenue Momentum and Booking Pace
Q4 group room revenue rose 5% year-over-year; 2025 group room revenue pace is currently pacing ~5% ahead of prior-year, and the company added over $13.0 million in additional group room revenue during Q4 for 2025 (≈6% increase vs. prior-year quarter).
Successful Asset Conversions and Outperformance
Conversions include Crowne Plaza La Concha → Autograph after a $35.0M investment and La Pavion → Tribute following a $19.0M investment; La Pavion outperformed underwriting (north of 40% outperformance in January) and recorded RevPAR > $900 during Super Bowl nights.
Strong Individual Property Performance
Embassy Suites Crystal City delivered a 22% increase (Q4) driven by GrowAHT initiatives; Le Méridien Fort Worth Downtown achieved total revenue growth 21% ahead of budget shortly after opening.
Margin Expansion and Cost Savings
Gross operating margins expanded ~141 basis points in Q4 year-over-year; Renaissance Nashville gross operating profit increased 10% on 3% total hotel revenue growth; procurement/supply chain initiatives yielded >$130,000 in food cost savings for the full year.
Portfolio Size and Liquidity
As of 12/31/2024 the consolidated portfolio consisted of 73 hotels (17,644 rooms); cash and cash equivalents were $112.9M with restricted cash of $107.6M and net working capital of approximately $122.0M.
Asset Sale with Attractive Metrics
Post-quarter sale of the 115-room Courtyard Boston Downtown for $123.0M ($1,070,000 per key) with a trailing NOI cap rate of ~5.9% (TTM ended 09/30/2024) and ~12.3x hotel EBITDA on the same period.
Balance Sheet Actions and Refinancing Progress
Completed multiple refinancings (including a $580.0M refinancing post-quarter), secured a new $121.5M nonrecourse loan, used ~$72.0M of excess proceeds to pay off remaining strategic financing, and raised ~$195.0M gross from Series J & K non-traded preferred offerings since 2022.
Capex Plan to Support Performance
2025 capital expenditure program expected to be $95.0M–$115.0M to execute PIPs, brand renewals and property upgrades aimed at driving long-term RevPAR and EBITDA gains.